The Justice Department said Tuesday that CVS Health will pay $315 million to resolve allegations that its pharmacies unlawfully dispensed opioids and other controlled substances, settling a whistleblower lawsuit that had expanded into a federal enforcement action.
The agreement stems from a False Claims Act complaint first brought in 2019 by Hillary Estright, a former CVS employee, and a subsequent complaint filed by the federal government in 2024. The government alleged that CVS knowingly filled prescriptions that lacked a legitimate medical purpose, were invalid, or fell outside accepted professional standards.
Prosecutors also claimed that CVS’s internal performance metrics pushed pharmacists to fill such prescriptions in order to boost corporate profits. The settlement does not include an admission of liability, and the government maintains that its claims were well-founded.
Compliance Measures and DOJ Response
As part of the deal, CVS must adopt additional safeguards to ensure that opioids and other controlled substances are dispensed only when medically appropriate. The Justice Department highlighted that the remedial measures include proactive monitoring of opioid prescribing patterns.
“Today’s settlement requires CVS to implement additional safeguards to ensure that prescriptions for opioids and other controlled substances are dispensed only when medically appropriate,” said Assistant Attorney General Brett A. Shumate. “The remedial measures in this agreement — including proactive monitoring of opioid prescribing patterns — will provide critical protections for patients and federal healthcare programs. The Department of Justice will continue to take steps to prevent the unlawful dispensing of opioids.”
The resolution follows a pattern of similar enforcement actions against large pharmacy chains. Walgreens and Kroger have reached opioid-related settlements in recent years, and Walmart settled a comparable case last August. CVS previously agreed to pay $4.9 billion to states and political subdivisions in 2022 to resolve a related lawsuit.
CVS Health said it disagrees with the government’s allegations and stressed that the settlement admits no wrongdoing. The company pointed to its more than 27,000 pharmacists, who it said are highly trained in the safe and appropriate use of medications, and touted its programs designed to help pharmacists make the best decisions for patients.
“We strongly disagree with the claims made in this case, and our settlement with the DOJ admits no wrongdoing,” CVS said in a statement. “We’re pleased to move forward and put this litigation behind us.”
The case underscores the Justice Department’s continued scrutiny of opioid distribution practices and the role of corporate incentives in pharmacy operations. The settlement’s monitoring requirements are intended to prevent future violations and protect federal healthcare programs.
